Annals of Cancer Therapy and Pharmacology: Immunotherapy Drug for Patients with HPV-Related Cancers

Immunotherapy Drug for Patients with HPV-Related Cancers
      Immunotherapy drugs shrank the tumors of some patients with advanced human papillomavirus (HPV)-related cancers. The drug, bintrafusp alfa (also called M7824), was designed to simultaneously bind to two target proteins—PD-L1 and TGF-beta—that help prevent the immune system from effectively attacking tumor cells.
             Human Papillomavirus slow-growing cancer can be found early with regular Pap smear, also called a Pap test, a procedure in which cells are scraped from the cervix and looked at under a microscope. Mortality rates have been decreasing in the United States, thanks largely to the widespread use of the Pap smear as a screening tool. In addition to the Pap smear, DNA tests can also detect HPV strains that pose a cervical cancer risk. Cervical cancer incidence and mortality, however, remain significantly higher in low-income countries.
       Symptoms of this disease often go undetected until cancer becomes invasive. Abnormal vaginal bleeding is the most common sign of cervical cancer.
      Patients with advanced cancers, including cervical cancer, anal cancer, and squamous cell carcinoma of the head and neck. Most of the patients had tumors that tested positive for HPV.
       Among all participants, patients responded to the drug (their tumors shrank) Exit Disclaimer. Of the 36 patients with HPV-positive tumors, patients responded.
Four of the responses lasted longer than 18 months, and 11 out of 15 responses were still ongoing when the data were analyzed. Two patients showed no detectable signs of cancer following treatment.
         The survival of 9 to 11 months seen in patients with HPV-related cancers in previous trials testing immune checkpoint inhibitors that target PD-1 or PD-L1.
       M7824 drug is a promising agent for patients with HPV-related cancers and may potentially benefit these patients’ more than traditional checkpoint therapies.

       The researchers saw responses in patients whose tumors were infected with a variety of carcinogenic HPV types, including HPV16 and HPV18, which are responsible for most HPV-related cancers. Patients who responded had various types of cancer, including squamous cell cervical cancer, cervical adenocarcinoma, squamous cell anal carcinoma, and squamous cell head and neck cancer.

Comments

Popular posts from this blog

Hepatitis C Care Cascade In IV Drug Users: Scientific Journal of Gastroenterology and Hepatology (SJGH)- ISSN : 2641-5585

Using Artificial Intelligence to Catch Irregular Heartbeats: American journal of Cardiology and Cardiovascular diseases (AJCCVD), ISSN 2641-2438

Scientific Journal of Animal and Veterinary Science: Radiation Therapy for Dogs